According to the National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Medical practitioners warn that acquired hemophilia can cause life-threatening bleeding complications in severe cases. In around 50% of cases, there is an identifiable underlying clinical condition; in the other 50%, no cause is known i.e. it is idiopathic. The acquired hemophilia treatment market is anticipated to grow at a CAGR of 3.25% during the forecast period of 2023-2030. 

Rise in Geriatric Population Remains as The Key Driver

Acquired hemophilia is caused by autoantibody formation to FVIII4. The incidence rate of the condition is 0.2 to 1.48 cases per million individuals per year. Considering the sexes, acquired hemophilia affects both males and females equally. However, the incidence of this condition appears greater in older adults over 65 years of age. In such a population, bleeding episodes may be severe, difficult to control, and fatal in some cases. The incidence of acquired hemophilia A in individuals aged 65 years is 0.28 patients per million per year, but increases to 5.97 in ages between 65 to 85 years and reduces to 16.6 in individuals older than 85 years. Overall, more than 80% of diagnosed cases are aged 60 years. These data are believed to be likely underestimated because of the chances of undiagnosed and unreported cases. 

Traditional Therapies Continue to Dominate to the Market

The types of traditional therapies used to treat acquired hemophilia are steroid treatment, cytotoxic therapy, and immunomodulatory therapy. The advanced treatments segmentation includes recombinant activated factor VII/NovoSeven RT, recombinant porcine factor VIII, activated prothrombin complex concentrate (aPCC)/FEIBA, and desmopressin (DDAVP). Though traditional therapies dominate the market in 2021, advanced therapies are expected to take up their share significantly during the forecast period. The advanced therapies are proving their efficiency across the globe, resulting in increased uptake. 

Hospitals Remain as The Key Healthcare Setting for Therapy

Hospitals remain as the key healthcare setting due to availability of broad range of therapeutic options. Additionally, the availability of registered medical practitioners along with reimbursement policies make hospitals most preferable healthcare setting for management and treatment of hemophilia. Clinics are expected to grow fastest during the forecast period as they are cost effective and less complex in comparison to hospitals. 

APAC Promises Opportunities During the Forecast Period

After scrutiny of the global acquired hemophilia treatment market, the regional trends, market sizes, and the overall growth paired with the latest and anticipated events, North America is observed to be the most dominant regional market for acquired hemophilia treatment. However, Asia Pacific promises significant opportunities during the forecast period, growing at the highest CAGR of 5.97% from 2023-2030. 

Focus on Product Pipeline Remains the Key Focus Among Market Players

The global acquired hemophilia treatment market is observed as a diversified and competitive market comprising a large number of players. The spearheading market players include Roche, Sanofi, Pfizer, Baxter, Takeda, CSL Behring; Novo Nordisk A/S; and others. The major market participants implemented growth strategies such as partnerships, new product launches, and operational expansion to gain a competitive advantage. The top most strategy followed by top competitors includes trial announcements. Key companies such as Pfizer, F. Hoffman LA Roche, Sanofi, Genentech Inc and Novo Nordisk are actively involved in product trials placed for approvals. 

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Acquired Hemophilia Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Acquired Hemophilia Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Acquired Hemophilia Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Acquired Hemophilia Treatment market?
• Which is the largest regional market for Acquired Hemophilia Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Acquired Hemophilia Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Acquired Hemophilia Treatment market worldwide?